Chemical synthesis, characterisation and in vitro and in vivo metabolism of the synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-45 with metabolite confirmation in urine samples from known drug users by McKenzie, C et al.
McKenzie, C and Sutcliffe, Oliver and Read, KD and Scullion, P and Epe-
molu, O and Fletcher, D and Helander, A and Beck, O and Rylski, A and
Antonides, LH and Riley, J and Smith, SA and Nic Daeid, N (2018)Chem-
ical synthesis, characterisation and in vitro and in vivo metabolism of the
synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-
45 with metabolite confirmation in urine samples from known drug users.
Forensic Toxicology, 36 (2). pp. 359-374. ISSN 1860-8965
Downloaded from: http://e-space.mmu.ac.uk/620515/
Version: Published Version
Publisher: Springer for the Japanese Association of Forensic Toxicology
DOI: https://doi.org/10.1007/s11419-018-0413-1
Usage rights: Creative Commons: Attribution 4.0
Please cite the published version
https://e-space.mmu.ac.uk
Vol.:(0123456789) 
Forensic Toxicology (2018) 36:359–374 
https://doi.org/10.1007/s11419-018-0413-1
ORIGINAL ARTICLE
Chemical synthesis, characterisation and in vitro and in vivo 
metabolism of the synthetic opioid MT‑45 and its newly identified 
fluorinated analogue 2F‑MT‑45 with metabolite confirmation in urine 
samples from known drug users
Craig McKenzie1  · Oliver B. Sutcliffe2  · Kevin D. Read3 · Paul Scullion3 · Ola Epemolu3 · Daniel Fletcher3 · 
Anders Helander4  · Olof Beck4  · Alexia Rylski4 · Lysbeth H. Antonides1,2,5 · Jennifer Riley3 · Shannah A. Smith1  · 
Niamh Nic Daeid1,5 
Received: 19 December 2017 / Accepted: 21 March 2018 / Published online: 5 April 2018 
© The Author(s) 2018
Abstract
Purpose The detection of a novel psychoactive substance, 2F-MT-45, a fluorinated analogue of the synthetic opioid MT-45, 
was reported in a single seized tablet. MT-45, 2F-, 3F- and 4F-MT-45 were synthesised and reference analytical data were 
reported. The in vitro and in vivo metabolisms of MT-45 and 2F-MT-45 were investigated.
Method The reference standards and seized sample were characterised using nuclear magnetic resonance spectroscopy, ultra-
performance liquid chromatography–quadrupole time of flight mass spectrometry, gas chromatography–mass spectrometry, 
attenuated total reflectance-Fourier transform infrared spectroscopy and Raman spectroscopy. Presumptive tests were per-
formed and physicochemical properties of the compounds determined. Metabolite identification studies using human liver 
microsomes, human hepatocytes, mouse hepatocytes and in vivo testing using mice were performed and identified MT-45 
metabolites were confirmed in authentic human urine samples.
Results Metabolic pathways identified for MT-45 and 2F-MT-45 were N-dealkylation, hydroxylation and subsequent glu-
curonidation. The major MT-45 metabolites identified in human in vitro studies and in authenticated human urine were 
phase I metabolites and should be incorporated as analytical targets to existing toxicological screening methods. Phase II 
glucuronidated metabolites were present in much lower proportions.
Conclusions 2F-MT-45 has been detected in a seized tablet for the first time. The metabolite identification data provide 
useful urinary metabolite targets for forensic and clinical testing for MT-45 and allows screening of urine for 2F-MT-45 and 
its major metabolites to determine its prevalence in case work.
Keywords Novel psychoactive substances · MT-45 · 2F-MT-45 · Metabolite identification · Synthetic opioids · Clinical and 
forensic toxicology
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Introduction
MT-45 [1-cyclohexyl-4-(1,2-diphenylethyl)piperazine], also 
known as IC-6, NSC 299236 and CDEP, is a synthetic opi-
oid developed as a therapeutic drug candidate in the 1970s 
by the Dainippon Pharmaceutical Co. in Japan. MT-45 has 
never been commercially available as a therapeutic agent; 
however, it has appeared on the illicit recreational drug 
market in recent years, but not extensively [1–6]. MT-45 is 
structurally distinct from other therapeutic opioids (Fig. 1a) 
and has structural similarities to the dissociative drug 
diphenidine (Fig. 1f) which is an N-methyl-d-aspartic acid 
(NMDA) receptor agonist. MT-45 is a selective μ-opioid 
receptor (MOR-1) agonist showing nM binding affinities to 
MOR-1, but is less potent than morphine, with considerably 
lower δ- and κ-opioid receptor (DOR-1 and KOR-1) affini-
ties [1]. The racemic mixture has opioid-like properties in 
animal models with a potency similar to morphine, with 
the (S)-enantiomer being considerably more potent than the 
(R)-isomer [4, 7–11]. Antinociceptive (reduced sensitivity 
to pain) effects were studied in vivo using a radiant heat 
tail flick assay in mice, showing that MT-45 had analge-
sic properties similar to morphine [1], which were further 
confirmed by Montesano et al. [12]. Users reporting their 
subjective experiences with the drug on online fora have 
often reported dissociative effects after consuming MT-45 
[13–15], and such effects may be mediated via the NMDA 
receptor; however, no formal studies on the NMDA recep-
tor affinity of MT-45 or its metabolites have been reported.
MT-45 was first detected on the illicit market in seized 
samples in Japan [16] and was first reported in Europe by 
the STRIDA project in Sweden in nine nonfatal intoxica-
tion cases [17]. Detection of MT-45 in biological fluids was 
reported to the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) in relation to 28 fatal and 12 
nonfatal intoxications in Sweden, the substance being impli-
cated in 19 of the fatalities either as the cause of death or 
as a contributing factor and was commonly detected with 
other psychoactive substances [18]. Unusual side effects, 
including hearing impairment and loss, severe bilateral cata-
racts, folliculitis and dermatitis were reported in individuals 
following nonfatal intoxications with MT-45 [17, 19, 20]. 
In the USA, MT-45 and the benzodiazepine etizolam were 
detected and quantified in whole femoral blood relating to a 
drug-related fatality (520 and 35 ng/mL, respectively), and 
MT-45 was also detected in urine, vitreous humor and bile 
[21]. Two further MT-45-related fatalities were reported in 
the USA in 2013 [22]. MT-45 was detected (2900 ng/mL) in 
postmortem femoral blood in a German fatality, where the 
user appeared to die shortly after taking the drug [23]. Both 
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Fig. 1  Chemical structures of a MT-45, including the structural notation used for nuclear magnetic resonance (NMR) spectroscopy data using 
the system reported by [16], b 2F-MT-45, c 3F-MT-45, d 4F-MT-45, e 2FPPP (fluorolintane), f diphenidine and g 2-methoxphenidine (2-MXP)
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Papsun et al. [21] and Fels et al. [23] noted that MT-45 in 
femoral blood appeared unstable (and of unknown stabil-
ity in other matrices) with concentrations decreasing > 50% 
from original concentrations over approximately 1 year, 
despite samples being stored at −20 °C until analysis; how-
ever, the breakdown products of MT-45 have not been identi-
fied. Reviews of the scientific literature related to MT-45 [2, 
24–26] highlight a lack of availability of metabolic studies, 
although one such study has recently been published pro-
viding in vitro data using rat hepatocytes and in vivo data 
in mice [12].
A review of the prevalence of MT-45, its mode of use 
and user experiences taken from online fora is available, 
together with a report on MT-45 anecdotally being seen as a 
relatively undesirable recreational drug [27, 28]. In the UK, 
MT-45 was designated a Class A substance under the Misuse 
of Drugs Act 1971 (as amended) in February 2015 and is a 
Schedule 1 substance in the Misuse of Drugs Regulations 
2001 (as amended) having no legitimate medical applica-
tion [24]. In May 2016, MT-45 was brought under interna-
tional control by the United Nations Office for Drugs and 
Crime (UNODC) as a Schedule I substance under the Single 
Convention on Narcotic Drugs of 1961, as amended by the 
1972 Protocol [25]. In July 2017, it was listed as a controlled 
substance by China, prohibiting its sale and export, one of 
138 substances controlled in this way since 2015 [29]. One 
common response of novel psychoactive substance (NPS) 
drug synthesis laboratories supplying the illicit drug mar-
ket, most commonly, but not exclusively, located in China, 
following a legislative ban, is to manipulate the structure of 
the banned substance to a small degree, evading the ban but 
retaining similar effects and potency. One such manipulation 
is the substitution of a hydrogen atom on the molecule with a 
fluorine atom. It might be expected therefore that, following 
the ban, fluorinated analogues of MT-45 may appear on the 
illicit drug market.
This study reports the first known identification of a 
fluorinated MT-45 analogue, detected in a tablet recovered 
in Manchester, UK, in October 2016, and describes the sub-
stance’s analytical characterization and the synthesis of three 
fluorinated MT-45 analogue reference standards (2F-, 3F- 
and 4F-MT-45) to unequivocally confirm identity. This study 
also reports the elucidation and identification of phase I and 
II metabolites of MT-45 and, for the first time, 2F-MT-45. 
The in vitro and in vivo metabolisms of MT-45 and 2F-MT-
45 have been studied using human liver microsomes, human 
hepatocytes, mouse hepatocytes and mouse in vivo testing, 
and the data from the different techniques are compared as 
well to previously published MT-45 metabolite identification 
data [12]. MT-45 metabolites identified in vitro and mouse 
in vivo studies have, for the first time, been analytically con-
firmed in reanalysed human urine samples from individuals 
known to have ingested MT-45.
Materials and methods
Synthesis of reference standards
1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine dihydrochlo-
ride (MT-45, Fig. 1a) and its fluorinated derivatives (2F-
MT-45, Fig. 1b; 3F-MT-45, Fig. 1c; 4F-MT-45, Fig. 1d) 
were prepared using an adaptation of the method reported 
by Geyer et al. [30]. The products were structurally char-
acterized by 1H nuclear magnetic resonance (NMR), 13C 
NMR, 19F NMR, gas chromatography–mass spectrometry 
(GC–MS), attenuated total reflectance-Fourier transform 
infrared (ATR-FTIR) spectroscopy and Raman spectros-
copy (see supplementary material). Yields of products (after 
recrystallization from diethyl ether): 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine dihydrochloride (MT-45, 20%); 
1-cyclohexyl-4-(1-(2-fluorophenyl)-2-phenylethyl)pipera-
zine dihydrochloride (2F-MT-45, 18%); 1-cyclohexyl-4-(1-
(3-fluorophenyl)-2-phenylethyl)piperazine dihydrochloride 
(3F-MT-45, 19%); 1-cyclohexyl-4-(1-(4-fluorophenyl)-
2-phenylethyl)piperazine dihydrochloride (4F-MT-45, 18%).
Seized illicit tablet
An off-white/cream square tablet in a clear snap-bag labelled 
with “2FPPP”, an alternative name for the dissociative drug 
fluorolintane, was submitted to Manchester Metropolitan 
University via Greater Manchester Police on the 15th Octo-
ber 2016 following the Mantra Festival, Greater Manchester, 
UK. The tablet was 6 mm in length × 6 mm width × 4 mm in 
Fig. 2  Photograph of off-white/cream square tablet (in a clear snap-
bag labelled with “2FPPP”), with 6-mm length, 6-mm width and 
4-mm height/depth
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height/depth. The molecular structure of 2FPPP is shown in 
Fig. 1e and the seized tablet is shown in Fig. 2.
Chemical characterisation
GC–MS analysis was carried out on 1-mg/mL sample ana-
lyte solutions in high-performance liquid chromatography 
(HPLC) grade methanol using a 7820A gas chromatograph 
coupled to a 5977E mass spectrometer (Agilent Technolo-
gies, Santa Clara, CA, USA). Injection mode: 1-μL sam-
ple injection and 25:1 split, injection port temperature: 
250  °C, carrier gas: He, flow: 1 mL/min. Column: DB-
1MS, 25 m × 0.2 mm i.d.,  film thickness 0.33 μm (Agilent 
Technologies). GC oven: 40 °C held for 1 min; 40 °C/min to 
300 °C held for 4 min. Transfer line: 280 °C. The mass spec-
trometer was operated in electron ionization (EI) mode. Ioni-
zation conditions: 70 eV in full scan mode (50–550 amu), 
ion source: 230 °C, quadrupole: 150 °C.
ATR-FTIR spectroscopy was carried out using a CARY 
630 system (Agilent Technologies).
NMR spectroscopy analyses were performed using a 
Bruker AVANCE III HD 500-MHz spectrometer (Bruker, 
Billerica, MA, USA) running under TopSpin v.3.2.5 
equipped with a QCI-F cryo-probe at a sample compart-
ment temperature of 25 °C. Samples were prepared in  CDCl3 
(~ 10 mg in 1 mL). Two drops of saturated sodium bicarbo-
nate in  D2O was added and the samples shaken thoroughly to 
extract the salt. Once the layers of  CDCl3 and  D2O had fully 
separated, a 0.7-mL aliquot of the  CDCl3 layer was recov-
ered and transferred to NMR tubes for analysis. The data was 
analysed using TopSpin v.3.2.3. The residual solvent signals 
at δ = 7.26 ppm for 1H and δ = 77.16 ppm for 13C were used 
as internal references. Hexafluorobenzene was used to refer-
ence the 19F spectra (δ = −164.9 ppm). Characterisation of 
the compound was performed using 1H NMR, 13C NMR 
(1H decoupled), 19F NMR (1H decoupled), double-quantum 
filtered correlated spectroscopy (COSY-DQF), 1-bond 1H-
13C distortionless enhancement by polarisation transfer 
(DEPT)-135 edited heteronuclear single quantum correla-
tion (HSQC) spectroscopy, 1H-13C heteronuclear multiple 
bond coherence (HMBC) spectroscopy, nuclear Overhauser 
enhancement spectroscopy (NOESY) and 19F-1H heteronu-
clear Overhauser enhancement spectroscopy (HOESY; see 
supplementary material for all spectral characterisations). 
The numbering scheme for the structure is shown in Fig. 1a 
[16].
Ultra-performance liquid chromatography–quadrupole 
time-of-flight mass spectrometry (UPLC–QToF-MS) of the 
synthesised reference standards and metabolomics samples 
was performed using an Acquity UPLC instrument consist-
ing of a binary pump, autosampler (held at 4 °C), vacuum 
degasser and column oven (held at 40 °C) coupled to a Xevo-
QToF (Waters Corporation, Milford, MA, USA). Mobile 
phases were (A) LC–MS grade water with 0.1% formic 
acid and (B) acetonitrile with 0.1% formic acid. The gra-
dient used was: 0.0–0.5 min: 2% B; 0.5–5.0 min: 2–95% 
B; 5.0–5.99 min: 95% B; and 6.0–7.0 min: 2% B for equi-
libration. Flow rate was 0.5 mL/min and 2 μL of sample 
was injected onto a BEH  C18 50 × 2.1 mm, 1.7 µm particle 
size column (Waters Corporation). The QToF was operated 
in positive ionisation mode with a source temperature at 
120 °C, a desolvation temperature at 500 °C and a capillary 
voltage at 2.25 kV. QToF-MS analysis was carried out with 
a collision energy at 6 V and QToF  MSe acquisition was 
carried out using collision energy ranging from 20 to 40 V. 
Once QToF-MS, and  MSe data were processed, MS/MS data 
acquisition was utilised for selected parent ion accurate mass 
data to determine accurate product ion data.
Raman spectroscopy was performed using a proprietary 
analytical system developed at the University of Dundee (see 
supplementary material).
The pKa-basic and partition coefficient (log P) values for 
MT-45 and its fluorinated analogues were experimentally 
derived using a Sirius T3 system (Sirius Analytical Instru-
ments, Sussex, UK).
A range of presumptive colour tests were carried out 
using 1–2 mg of the synthesised reference standards and 
the seized tablet, with reagents prepared and tests performed 
in accordance with UNODC guidelines [31].
Metabolite identification
Full method details for the in vitro metabolite identification 
studies are provided in the supplementary material.
Pooled human liver microsome incubations
MT-45, 2F-MT-45 and positive controls were incubated 
in pooled human liver microsome (pHLM; Thermo Fisher 
Scientific, Waltham, MA, USA) incubations at 37 °C with 
and without uridine 5′-diphosphoglucuronic acid (UDPGA). 
Verapamil was used as the positive control for incubations 
without UDPGA (phase I metabolism) and propranolol as 
the positive control for incubations with UDPGA (phase 
II metabolism). Procedure: 450 µL of liver microsomes 
(1.11 mg/mL) and 45 µL of cofactor (nicotinamide adenine 
dinucleotide phosphate (NADPH) or UDPGA/NADPH) 
were added to wells of a 96-deep-well 2-mL plate (incuba-
tion plate) kept at 37 °C; 5 µL of 5 μM test compound in 
dimethyl sulphoxide (DMSO; Fisher Scientific, Loughbor-
ough, UK) was added and a 50-µL aliquot of the incubation 
mixture was immediately removed and added to 200 µL of 
acetonitrile (ACN; Fisher Scientific) to terminate the reac-
tion, providing an initial (t = 0) sample. Further, 50-µL ali-
quots of the incubation mixtures were removed at 5, 15, 30 
and 60 min. All samples were centrifuged to sediment any 
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precipitated protein (3270 rpm for 10 min). A 150-µL vol-
ume of the supernatant was removed, diluted with 50 µL of 
Milli-Q water in a 96 deep-well 2-mL plate (analysis plate) 
and sealed prior to analysis by UPLC–QToF-MS.
In vitro human and mouse hepatocyte incubations
Metabolic stability studies were performed using cryopre-
served hepatocytes; either mouse (Mheps: mouse CD1 Cryo 
Hep Female Suspension Pool 20 Donor, 4–8 million recov-
erable cells, MSCS20; Thermo Fisher Scientific) or human 
(Hheps: Human Cryo Hep Suspension Pool 50 Donor, mixed 
gender, HMCS50; Thermo Fisher Scientific). 7-Ethoxycou-
marin and 7-hydroxycoumarin were used as positive con-
trols. Reaction initiation and sampling: 200 μL of working 
solution containing test compound at 5 μM in DMSO was 
added to 200 μL of cell suspension to initiate the reaction. 
A 20-μL aliquot of the incubation mixture was removed 
immediately and added to 80 μL of acetonitrile containing 
an internal standard (50 ng/mL donepezil). Further 20-μL 
aliquots were removed to a 96 deep-well 2-mL plate (analy-
sis plate) at the following timepoints: 3, 6, 9, 15, 30, 60, 90 
and 120 min. A 100-μL volume of water/acetonitrile (80:20, 
v/v) was added to all samples and the analysis plate was cen-
trifuged at 2800 rpm for 10 min at room temperature prior 
to injection and analysis of samples by UPLC–QToF-MS.
In vivo mouse metabolite identification studies
MT-45 and 2F-MT-45 were dosed orally by gavage as a solu-
tion at 10 mg free base/kg (dose volume: 10 mL/kg; dose 
vehicle: 1.0% carboxymethyl cellulose) to female C57BJ/6 J 
mice (n = 1/compound). Blood samples (10 µL) were taken 
from each mouse tail vein pre-dose and then at 0.5, 1, 2, 4, 8 
and 24 h, mixed with 9 volumes of distilled water and stored 
frozen until analysed. The 24-h urine samples were also col-
lected for metabolite identification studies. The blood and 
urine samples were subjected to UPLC–QToF-MS analysis 
and the metabolites were identified. All samples were pro-
cessed using MetaboLynx-XS software (Waters Corpora-
tion) to identify possible metabolites from MS data. The 
list was reduced by a manual check of the data and an MS/
MS analysis was performed on peaks accepted as genuine 
metabolites.
Human metabolite identification studies
In addition to the identification of MT-45 metabolites identi-
fied in the in vitro and mouse in vivo, the study in human 
urinary analysis was carried out using urine samples col-
lected from two analytically confirmed intoxication cases, 
two males aged 17 and 26 years (full details are provided in 
[17]) enrolled in the Swedish STRIDA project on NPS [17, 
19]. The 17-year-old had 102 ng/mL of MT-45 in blood and 
43 ng/mmol of creatinine in urine. 11-Nor-9-carboxy-∆9-
tetrahydocannabinol, dextromethorphan and methiopropa-
mine were also detected in his urine. The 26-year-old had 
39 ng/mL of MT-45 in blood and 200 ng/mmol of creatinine 
in urine and 3-methoxyphencyclidine was also detected. The 
urine samples had been stored at −80 °C since the time of 
sampling to reanalysis for this study. The analysis was done 
by HPLC combined with high-resolution mass spectrom-
etry (HRMS), essentially as detailed elsewhere [32, 33], and 
involved a targeted search for the metabolites already iden-
tified in the human and mouse in vitro and mouse in vivo 
studies.
Results
Chemical characterisation of synthesised reference 
standards
UPLC–QToF-MS, GC–MS, ATR-FTIR spectroscopy, NMR 
(1H, 13C and 19F) spectroscopy and Raman spectroscopy data 
and experimentally derived pKa’s, log P (octanol/water) and 
log D7.4 (octanol/water) values for the characterisation of 
the synthesised reference standards were provided (see sup-
plementary material, section C). Log P is the partition coef-
ficient of the non-ionised form of the analyte, whilst log D 
is the pH-dependent coefficient of distribution for ionisable 
compounds such as the MT-45s at the physiological pH (pH 
7.4).
The MT-45 and fluorinated analogue reference standards 
were tested using a range of commonly used presumptive 
tests (see supplementary material). MT-45 and its fluori-
nated analogues gave similar, positive results for Scott’s 
(cobalt (II) thiocyanate) test, normally used as a presumptive 
test for cocaine, to those previously reported for the structur-
ally similar diphenidine and 2-, 3- and 4-methoxphenidine 
(MXP), most likely due to the presence of tertiary amines in 
all [31]. However, the MT-45s did not give a positive result 
in the modified Scott’s test, which allows them to be differ-
entiated from diphenidine and the MXPs [McKenzie et al., 
unpublished data]. The MT-45s all gave a yellow result in 
the Mecke’s test as did diphenidine and 2-, 3- and 4-MXP 
[McKenzie et al., unpublished data]. Diphenidine and the 
MT-45s produced similar responses to the Marquis test 
(immediate yellow) but were differentiated from the MXPs 
which produce a transient pink or red/brown reaction [30].
Identification of seized material
The seized tablet was analysed by GC–MS, ATR-FTIR spec-
troscopy and NMR spectroscopy. Presumptive testing pro-
vided the same results for the seized tablet as observed for 
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MT-45 and its fluorinated analogue reference standards. Pre-
liminary GC–MS analysis indicated that it contained a previ-
ously unreported fluorinated MT-45 derivative rather than 
2FPPP. The mass spectrum of the seized sample revealed 
a molecular ion at m/z 366, and a comparison to the mass 
spectra of the MT-45 and 2F-MT-45 reference standards is 
provided in the supplementary material. MT-45 could be 
chromatographically separated from the fluorinated MT-
45s; however, the regioisomers could not be separated by 
retention time or mass using GC–MS. Comparison of the 
seized tablet with the synthesised reference standards using 
ATR-FTIR spectroscopy indicated that 2F-MT-45 was pre-
sent with two discriminatory areas in the fingerprint region 
of the spectra, 800–650 nm and 1550–1400 nm (see sup-
plementary material).
NMR spectroscopy data for the seized sample unequivo-
cally confirmed the presence of 2F-MT-45 in the seized 
tablet along with unidentified excipients (Table 1). The data 
indicated the presence of a mono-fluorinated diphenylethyl 
group, a piperazine group (broadened by exchange pro-
cesses) and a cyclohexane group. The connections between 
these groups and the position of the fluorine were deter-
mined using HMBC and NOESY/HOESY data (see sup-
plementary material). The HMBC/NOESY/HOESY correla-
tions to/from the 1′ proton confirmed that the molecule was 
fluorinated at the 1′-2 position. This was further confirmed 
when the 1H NMR and 19F NMR data from the F-MT-45 
reference standards were compared with the seized sam-
ple (Figs. 3 and 4). The position of the fluorine singlet in 
the decoupled spectra showed the identical signals for the 
2F-MT-45 and the seized sample (both δ: −119.6 ppm), and 
the proton-coupled data provides greater localised structural 
information and further evidence that the seized sample con-
tains 2F-MT-45. To the author’s knowledge, this is the first 
identification of a fluorinated MT-45 analogue in a seized 
sample.  
Table 1  13C, 1H and 19F nuclear magnetic resonance data for the seized tablet and a 2F-MT-45 reference standard (ref. std.), with a structural 
numbering system as used by [16] and as shown in Fig. 1a
No. Seized sample in  CDCl3
Chemical shifts, δ in ppm
2F-MT-45 ref. std. in  CDCl3
Chemical shifts, δ in ppm
1H 13C 19F 1H 13C 19F
2/6 2.58, 2/6 overlaps with 3/5, 
total integral 8H, br
49.37,  CH2 2.58, 2/6 overlaps with 3/5, 
total integral 8H, br
49.43,  CH2
3/5 2.54, br 50.34, br,  CH2 2.55, br 50.42, br,  CH2
1′ 4.12, 1H, dd, J = 9.6, 5.6 Hz 63.59/63.56*, CH 4.12, 1H, dd, J = 9.7, 5.6 Hz 63.59/63.54*, CH
2′ 3.32, 1H, dd, J = 13.5, 
5.6 Hz
38.43,  CH2, d, J = 1.2 Hz 3.31, 1H, dd, J = 13.5, 
5.6 Hz
38.44,  CH2, d, J = 1.2 Hz
3.04, 1H, dd, J = 13.5, 
9.6 Hz
3.04, 1H, dd, J = 13.5, 
9.7 Hz
1′-1 – 125.68, C, d, J = 14.5 Hz – 125.67, C, d, J = 14.7 Hz
1′-2 – 161.52, C, d, J = 244.8 Hz −119.6 – 161.53, C, d, J = 244.8 Hz −119.6
1′-3 6.88, 1H, ddd, J = 10.2, 8.2, 
1.2 Hz
115.42, CH, d, J = 23.8 Hz 6.88, 1H, ddd, J = 10.2, 8.2, 
1.2 Hz
115.43, CH, d, J = 23.8 Hz
1′-4 7.13, 1H, overlapping 128.59, CH, d, J = 8.5 Hz 7.13, 1H, overlapping 128.56, CH, d, J = 8.5 Hz
1′-5 7.05, 1H, overlapping 123.62, CH, d, J = 3.4 Hz 7.05, 1H, overlapping 123.61, CH, d, J = 3.3 Hz
1′-6 7.29, 1H, td, J = 7.3, 1.7 Hz 130.05, CH, d, J = 4.9 Hz 7.29, 1H, td, J = 7.4, 1.8 Hz 130.06, CH, d, J = 4.9 Hz
2′-1 – 139.30, C – 139.35, C
2′-2/2′-6 7.04, 2H, overlapping 129.37, CH 7.04, 2H, overlapping 129.38, CH
2′-3/2′-5 7.14, 2H, overlapping 128.09, CH 7.14, 2H, overlapping 128.09, CH
2′-4 7.08, 1H 126.00, CH 7.09, 1H 126.00, CH
1″ 2.17, 1H, tt, J = 10.9, 
3.3 Hz
63.59/63.56*, CH 2.17, 1H, tt, J = 10.9, 
3.3 Hz
63.54/63.59*, CH
2″/6″ 1.86, 2H, brd, J = 12.1 Hz 29.14, 29.12,  CH2 1.86, 2H, brd, J = 12.1 Hz 29.20, 29.17,  CH2 
1.15, 2H, m 1.15, 2H, m
3″/5″ 1.76, 2H, brd, J = 13.0 Hz 26.02,  CH2 1.77, 2H, brd, J = 12.8 Hz 26.03,  CH2
1.19, 2H, m 1.21, 2H, m
4″ 1.60, 1H, m
1.07, 1H, qt, J = 12.4, 
3.3 Hz
26.43,  CH2 1.60, 1H, m
1.07, 1H, qt, J = 12.4, 
3.5 Hz
26.46,  CH2
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Metabolite identification studies
Metabolite identification studies were carried out using the 
synthesised MT-45 and 2F-MT-45 reference standards. No 
previous metabolite identification studies have been carried 
out on MT-45 using human liver microsomes or hepatocytes, 
although metabolites have previously been identified using 
rat hepatocytes and detected in mouse urine [12]. MT-45 has 
been reported in biological samples from fatal and nonfatal 
intoxications of drug users; however, no metabolites have 
been identified in human samples. 2F-MT-45 has not previ-
ously been reported in any intoxication cases and thus this 
work gives information on urinary metabolites should such 
a case arise in the future or to provide metabolite data to be 
Fig. 3  a 1H NMR data for the seized sample, and b 1H NMR data for the 2F-MT-45 reference standard. *Signals presumed to be originating 
from unknown excipient(s) present in the seized sample
Fig. 4  Comparison of a proton 
decoupled and b proton-coupled 
19F NMR spectra for the 
seized tablet from bag labelled 
“2FPPP” and the synthesised 
fluorinated MT45 reference 
standards
366 Forensic Toxicology (2018) 36:359–374
1 3
added to screening methods. Such studies are required to 
provide analytical targets for urinary metabolites for toxico-
logical screening methods in clinical and forensic toxicology 
studies. At the physiological pH (7.4) at which all metabo-
lomics studies were carried out, MT-45 and 2F-MT-45 are 
protonated and have log D7.4 values of 3.17 and 3.56 (see 
supplementary material), respectively, making them both 
relatively lipophilic substances.
In a previous in vitro study using rat hepatocytes [12], 
the identification of 14 MT-45 metabolites (10 phase I and 4 
phase II) was reported. In this study, 15 unique (plus 1, ten-
tatively identified) MT-45 metabolites have been identified 
following MT-45 incubation with human liver microsomes, 
human hepatocytes, mouse hepatocytes and using mouse 
in vivo studies (see Fig. 5). An additional metabolite (M17), 
previously identified by [12], was identified in human urine 
only in this study. The chromatographic and mass spec-
tral data for the metabolites identified (M1–M17) is pro-
vided in Table 2. Chromatograms and time-course data for 
MT-45 metabolite identification studies using human liver 
microsomes and human hepatocytes are provided in Fig. 6. 
Data for mouse hepatocyte and mouse in vivo experiments 
are provided in the supplementary information (section 
E). Twelve unique 2F-MT-45 metabolites were identified 
following 2F-MT-45 incubation with human liver micro-
somes, human hepatocytes, mouse hepatocytes and in vivo 
mouse studies, and these are summarised in Fig. 7 and 
Table 3 (2F-M1–2F-M12).    
Human in vitro studies
Five phase I MT-45 metabolites were detected following 
human in vitro studies (Fig. 6b). No phase II metabolites 
were detected in the human in vitro studies, suggesting that 
hepatic phase II metabolism was limited by the incubation 
conditions employed in this study. Three metabolites were 
identified following incubation of MT-45 with human hepat-
ocytes: M1, formed as a result of N-dealkylation and M2 
and M3, two mono-hydroxylated metabolites, (Figs. 5, 6a). 
Interestingly M1 (1,2-diphenylethylpiperazine) was not iden-
tified by Montesano et al. [12] in rat hepatocyte and mouse 
in vivo studies, who instead identified another N-dealkylated 
metabolite, 1-cyclohexyl-piperazine (labelled as M9 in that 
study, and M17 detected in human urine in this study).
M1 (1,2-diphenylethylpiperazine) was identified as one 
of three major metabolites, along with M2 and M3, using 
in vitro testing using human hepatocytes and human liver 
microsomes in this study and was also identified in verified 
MT-45
HU; MU; MH
M7, M8
[M+H]+ = 541
(C30H41N2O7)
HU; MH; HH; HM
M1
[M+H]+ = 267
(C18H23N2)
HU; MU
M9
[M+H]+ = 459
(C24H31N2O7)
HU; HH; HM
M2
HU; MU; MH
M5
[M+H]+ = 365
(C24H33N2O)
HU; MH; HH; HM
M3
HU; MH; HM 
M4
[M+H]+ = 365
(C24H33N2O)
HU; MU
M11, M12
[M+H]+ = 557
(C30H41N2O8)
HU; MU
M15
[M+H]+ = 733
(C36H49N2O14)
Tentave
HU; MU
M16
[M+H]+ = 413
(C24H33N2O4)
HU; MU
M10, M13, M14
[M+H]+ = 557
(C30H41N2O8)
HU; HM: 
M6
[M+H]+ = 381
(C24H33N2O2)
+ 2xO 
+ 2xGlu + 4xO 
+ 2xO 
+ Glu
OH
[M+H]+ = 349
(C24H32N2) HO
HU
M17
[M+H]+ = 169
(C10H21N2)
+ 2xO
Glu O 
Glu O 
OH
HO 
+ Glu
22
Fig. 5  Overview of the metabolic profiling of MT-45 using human 
liver microsomes (HM), human hepatocytes (HH), mouse hepato-
cytes (MH), mouse urine (MU) from in vivo testing and authenticated 
human urine (HU) samples. Product ion spectra and structural eluci-
dation data are provided in the supplementary material, section F
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Fig. 6  Chromatographic profiles and time-course data following 
incubation of MT-45 with a human hepatocytes after 120 min, and b 
human microsomes after 60  min obtained by ultra-performance liq-
uid chromatography–quadrupole time-of-flight mass spectrometry. 
Metabolite labelling information can be found in Fig. 5 and Table 2
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human urine samples from users who had consumed MT-45 
(Fig. 5). M1 is structurally similar to the dissociative sub-
stance, diphenidine (1,2-diphenylethylpiperadine; Fig. 1f). 
Two additional, minor (as estimated by peak area) metabo-
lites were detected in the human liver microsome incuba-
tions only (Figs. 5 and 6b): the mono-hydroxylated metabo-
lite M4 and the di-hydroxylated metabolite M6.
Four phase I 2F-MT-45 metabolites were detected follow-
ing human in vitro studies (Fig. 7, Table 3); one metabolite 
resulted from N-dealkylation of the 2F-MT-45 parent struc-
ture and three due to mono-hydroxylations. As observed 
for MT-45, no phase II metabolites were detected in the 
human in vitro studies. Four metabolites were identified 
following incubation of 2F-MT-45 with human hepato-
cytes: 2F-M1 formed as a result of N-dealkylation and three 
mono-hydroxylated metabolites, 2F-M2, 2F-M3 and 2F-M4, 
were detected.
Mouse in vitro studies
Seven MT-45 metabolites were detected following incu-
bation of MT-45 with mouse hepatocytes for 2 h (Fig. 5, 
Table 2; see supplementary material for chromatograms), 
three of which had not been observed previously in the 
human in vitro studies. M5 is hydroxylated on the phene-
thyl moiety similar to M2 detected in the human in vitro 
studies; M7 and M8 are phase II metabolites with glucu-
ronidation occurring on the phenethyl moiety.
Seven 2F-MT-45 metabolites were detected follow-
ing incubation of 2F-MT-45 with mouse hepatocytes 
(Fig. 7, Table 3), three of which (2F-M5, 2F-M6 and 
2F-MT45
MH
2F-M7
[M+H]+ = 399
(C24H32N2O2F)
(-C6H10)
MH; HH; HM
2F-M1
[M+H]+ = 285
(C18H22N2F)
MU
2F-M8
[M+H]+ = 559
(C30H46N2O7F)
MU
2F-M10, 2F-M11. 2F-M12
[M+H]+ = 575
(C30H40N2O8F)
MH; HH; HM
2F-M3, 2F-M4, 
MH
2F-M6
[M+H]+ = 383
(C24H32N2OF)
+ 2xO + Gluc
Glu O  
MH; HH; HM 2F-M2
MH 2F-M5
[M+H]+ = 383
(C24H32N2OF)
MU
2F-M9
[M+H]+ = 477
(C24H30N2O7F)
[M+H]+ = 367
(C24H32N2F)
+ 2 x O + Glu
HO
OH
OH
HO
Glu O 
(-C6H10)
Fig. 7  Overview of the metabolic profiling of 2F-MT-45 using 
human liver microsomes (HM), human hepatocytes (HH), mouse 
hepatocytes (MH) and mouse urine (MU) from in vivo testing. Prod-
uct ion data and structural elucidation data are provided in supple-
mentary material, section G
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2F-M7) had not been detected in the human in vitro stud-
ies. Metabolite 2F-M5, like 2F-M2, was hydroxylated 
on the phenethyl moiety; 2F-M6 is a minor metabolite 
which, like 2F-M3 and 2F-M4, was hydroxylated on the 
cyclohexyl moiety; 2F-M7 was dihydroxylated, with one 
hydroxylation on the phenethyl moiety and the other on 
Table 3  Chromatographic and mass spectral data for 2F-MT-45 metabolites (phase I metabolites: 2F-M1–2F-M7; phase II metabolites: 
2F-M8–2F-M12)
Rt retention time
a Where metabolites have been detected in multiple experiments, one measured mass is provided as an example
b Difference between measured mass and calculated mass for molecular formula predicted. Maximum permissible difference = 10 parts per mil-
lion (ppm)
Metabolite Rt (min) Measured  massa Mol. formula 
[M + H]+
Calc. mass Diff. (mDa)b Diff. (ppm)b Product ions (meas-
ured mass)a
Description
2F-MT-45 4.54 367.2542 C24H32N2F 367.2550 − 0.8 − 2.2 181.1024, 166.0795, 
103.0566, 87.0934
Parent compound
2F-M1 3.56 285.1782 C18H22N2F 285.1853 1.5 5.3 199.0935, 179.0660, 
121.0463, 
103.0548, 87.0928
N-Dealkylation (–
C6H10)
2F-M2 3.61 383.2505 C24H32N2OF 383.2499 0.6 215.0671, 169.1721, 
119.0499, 87.0938
Mono-hydroxylation 
on the phenethyl 
moiety
2F-M3 3.88 383.2500 C24H32N2OF 383.2499 0.2 0.4 199.0925, 179.0862, 
121.0455
Mono-hydroxylation 
on the cyclohexyl 
moiety
2F-M4 4.01 383.2517 C24H32N2OF 383.2499 1.9 4.9 199.0925, 179.0862, 
121.0455
Mono-hydroxylation 
on the cyclohexyl 
moiety
2F-M5 3.78 383.2501 C24H32N2OF 383.2499 0.3 0.7 215.0907, 169.1737, 
119.0499, 87.0938
Mono-hydroxylation 
on the phenethyl 
moiety
2F-M6 4.13 383.2495 C24H32N2OF 383.2499 − 0.3 − 0.7 199.0919, 185.1661, 
121.0455
Mono-hydroxylation 
on the cyclohexyl 
moiety
2F-M7 2.90 399.2441 C24H32N2O2F 399.2488 − 0.7 − 1.8 215.0913, 185.1647, 
119.0524
Di-hydroxylation on 
the cyclohexyl and 
phenethyl moieties
2F-M8 3.16 559.2765 C30H46N2O7F 559.2820 − 5.5 − 9.8 215.0852, 119.0488, 
87.0926
Hydroxylation with 
subsequent glucu-
ronidation on the 
phenethyl moiety
2F-M9 1.95 477.2039 C24H30N2O7F 477.2037 0.2 0.4 215.0854, 119.0488, 
87.0926
N-Dealkylation (–
C6H10) followed by 
hydroxylation with 
subsequent glucu-
ronidation on the 
phenethyl moiety
2F-M10 2.43 575.2762 C30H40N2O8F 575.2769 − 0.7 − 1.2 399.2435, 231.0826, 
169.1708, 
135.0448
Hydroxylation and 
hydroxylation 
with subsequent 
glucuronidation on 
the 2-fluorophenyl 
phenethyl moiety
2F-M11 2.87 575.2729 C30H40N2O8F 575.2769 − 4.0 − 7.0 399.2461, 231.0807, 
169.1704
Hydroxylation and 
hydroxylation 
with subsequent 
glucuronidation on 
the 2-fluorophenyl 
phenethyl moiety
2F-M12 2.97 575.2726 C30H40N2O8F 575.2769 − 4.3 − 7.5 399.2433, 231.0811, 
169.1712
Hydroxylation and 
hydroxylation 
with subsequent 
glucuronidation on 
the 2-fluorophenyl 
phenethyl moiety
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the cyclohexyl moiety. The most prominent metabolites 
were the mono-hydroxylated 2F-M3 and 2F-M4 (m/z 383) 
metabolites.
Mouse in vivo studies
No MT-45 was detected in mouse urine collected after 24 h 
[see supplementary material, section E(ii)] and 10 metabo-
lites were detected. Phase II (glucuronidated) metabolites 
were the most abundant as estimated by peak area, in agree-
ment with previous findings in mouse urine [12]. Metabo-
lite M9 was the glucuronidated form of the N-dealkylated 
metabolite M1. Metabolites M10–M14 contained one 
hydroxyl group and one hydroxyl group with subsequent glu-
curonidation. M11 and M12 were hydroxylated on both the 
cyclohexyl moiety and phenethyl moiety with one hydroxyl 
group being subsequently glucuronidated. M10, M13 and 
M14 were di-hydroxylated on the phenethyl moiety, as 
indicated by the product ion at m/z 135 with one hydroxyl 
group being subsequently glucuronidated. Metabolite M15 
was di-hydroxylated and subsequently glucuronidated on the 
diphenylethyl moiety.
No 2F-MT-45 was detected in mouse urine collected 
after 24 h. Five glucuronidated metabolites were identi-
fied (Fig. 7, Table 3). Metabolite 2F-M8 was hydroxylated 
and subsequently glucuronidated on the phenethyl moiety. 
Metabolite 2F-M9 was the glucuronidated form of 2F-M1. 
Three other metabolites containing one hydroxyl group 
and one hydroxyl group with subsequent glucuronidation 
on the 2-fluorophenyl phenethyl moiety were detected: 
2F-M10, 2F-M11 and 2F-M12.
Confirmatory identification of MT‑45 metabolites in human 
urine
All MT-45 metabolites identified in the human and mouse 
in vitro and mouse in vivo studies (M1–M16) were detected 
in the human urine samples obtained from two analytically 
confirmed cases of MT-45 intoxication (Fig. 5), confirming 
the applicability of the methodology to case samples. The 
relative concentrations of metabolites were similar in both 
cases with M1 and M3 being the major metabolites, followed 
by M2 and M4 (each about 50% response in UPLC–QToF-
MS as compared with M1 and M3), M5 and M6 (about 
25%), M7–M9, M12 and M17 (~ 5–10%), and finally M10, 
M11, M13, M15 and M16 (~ 1% or less). An additional 
metabolite, M17, was detected in the human urine samples 
with similar peak areas to M5 and M6 (25–30% of M1 and 
M3). This N-dealkylated metabolite had not been identified 
in the human in vitro, the mouse in vitro and mouse in vivo 
studies using female C57 mice in this work, but had been 
previously identified as a significant metabolite in a study 
using rat hepatocytes and male ICR (CD-1®) mice [12].
Discussion
2F-MT-45 was detected in a single seized tablet and its 
identity confirmed by comparison with in-house synthe-
sised reference standards. It is noteworthy that there was 
some discrimination of the regioisomers using ATR-FTIR 
spectroscopy and Raman spectroscopy; however, they were 
most clearly distinguished using NMR spectroscopy, without 
the need to compare the resulting data with reference stand-
ards for structural elucidation. The sample was supplied in 
packaging labelled 2FPPP, indicating the presence of a dis-
sociative drug with some structural similarities to 2F-MT-
45. As far as the authors are aware, 2F-MT-45 has not been 
previously detected and the reasoning behind its synthesis in 
this case (deliberate or accidental) is unknown. This tablet 
was received for testing prior to the ban on production and 
export of MT-45 in China in July 2017 [29] and so it is pos-
sible that such compounds may enter the illicit drugs market 
in the future; however, MT-45 itself was relatively unpopular 
with users and a range of serious and unusual side effects 
have been linked with the drug [17, 20].
Both human hepatocyte and human liver microsomal 
incubations produced major N-dealkylated metabolites of 
MT-45 (M1) and 2F-MT-45 (2F-M1) which have structural 
similarities to dissociative drugs such as diphenidine and 
2-FPPP. Although the same metabolites (M1 and 2F-M1) 
were observed after incubation with mouse hepatocytes, 
they were less prominent, suggesting that N-dealkylation is 
more efficiently expressed in the human in vitro systems. 
It is postulated that these metabolites, structurally related 
to diphenidine, will not be excreted directly via the kidney 
into urine but will instead be recirculated in plasma, and they 
are more likely to have a larger distribution volume in the 
body. It is hypothesised that these metabolites are pharma-
cologically active and will interact with NMDA receptors 
once recirculated, and that they may be responsible, at least 
in part, for the dissociative effects of MT-45 reported by 
some users. Further studies of the pharmacological activity 
of M1 (and 2F-M1) against opioid and NMDA receptors are 
required to test this hypothesis.
Cryopreserved primary human hepatocytes such as those 
used in this study provide a model in vitro metabolite identi-
fication solution. They incorporate natural hepatic metabolic 
enzyme systems, co-substrates for phase I and II metabolism 
at physiological levels, and intact drug transporter systems. 
They are theoretically most likely to provide an authentic 
range of human metabolites in metabolite identification 
studies [34, 35]. They are, however, expensive relative to 
other in vitro systems and are relatively more complex to 
use than microsomes, require incubation under carbogen and 
have lower intracellular glutathione (GSH) and glutathione-
S-transferase (GST) activities than fresh hepatocytes. This 
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means that, if occurring in vivo, GSH conjugation of MT-45 
and 2F-MT45 may have been missed in vitro, although no 
evidence for GSH or GST conjugation was observed in the 
mouse in vivo study. In addition, human hepatocytes have 
a finite lifetime in suspension cultures (up to 5 h, although 
their activity is likely to decrease significantly after 2–3 h) 
and thus alternative in vitro systems are often used instead. 
Human liver microsomes represent a relevant system (and a 
more cost-effective approach) if the metabolism of the chem-
icals in question is known to be due to microsomal enzymes. 
In this study, the metabolites identified using human hepato-
cytes and human microsomes were very similar and three of 
the major MT-45 metabolites detected in human urine were 
also the major metabolites detected in the human in vitro 
methods. The use of pooled human S9 fraction or human 
liver microsomes combined with human cytosol has also 
been proposed as an alternative for NPS metabolomics stud-
ies focussed on identifying urinary target metabolites for 
toxicological screening purposes [36, 37].
The present study utilised a wide range of methodolo-
gies. MT-45 and 2F-MT-45 incubation with human hepat-
ocytes produced relatively lower amounts of metabolites 
(and less metabolites) as compared to incubations with 
human liver microsomes (see Fig. 6 for MT-45 data). In 
both the human hepatocyte and human liver microsome 
experiments, only phase I metabolites were identified, sug-
gesting that phase II metabolism of MT-45 and 2F-MT-45 
is either very slow, or is extrahepatic, and these metabo-
lites were not identified in the in vitro models used. Some 
minor phase II metabolism was observed in the mouse 
hepatocytes and these were also reported after MT-45 
incubation with rat hepatocytes [12].
Conclusions
A new fluorinated analogue of MT-45, 2F-MT-45, has been 
unequivocally identified in an illicitly produced tablet for the 
first time. The substance was identified using presumptive 
testing, GC–MS, UPLC–QToF-MS, ATR-FTIR spectros-
copy, Raman spectroscopy and NMR spectroscopy in com-
parison to fully characterised in-house synthesised reference 
standards for MT-45 and 2F-, 3F- and 4F-MT-45. Metabolic 
profiling has been carried out for MT-45 and 2F-MT-45, and 
HRMS data for the identified metabolites has been reported 
in human in vitro testing for the first time. The presence of 
the identified MT-45 metabolites has been also confirmed 
in authenticated human urine samples. It is recommended 
that the protonated molecular ions of the parent and major 
metabolites (M1–M4 and 2F-M1–2F-M4) are added to 
toxicological screening methods, and that, where possible, 
HRMS data from previous analyses are re-examined using 
data-mining techniques to increase the toxicovigilance infor-
mation available on the prevalence and use of such com-
pounds in different jurisdictions.
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